Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor ...Middle East

News by : (PR Newswire) -

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor )

Also on site :

Most Viewed News
جديد الاخبار